(Q61864692)

English

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) (English)

0 references

0 references

0 references

National Cancer Institute

0 references

country

United States of America

0 references

main subject

maximum tolerated dose

0 references

start time

29 April 2015

0 references

end time

1 December 2020

0 references

number of participants

81

0 references

clinical trial phase

phase I clinical trial

0 references

phase II clinical trial

0 references

research site

National Institutes of Health

0 references

minimum age

3 year

0 references

maximum age

35 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02390752

0 references

(Q61864692)

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)